Chase AIPricingFAQs
Display currency
Loading news…

AveXis

ClosedOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring).
Dallas, Texas, United States Founded 2013 11-50 employees For Profit

AveXis is a Biotech company is focused on developing gene therapy for patients with rare and life-threatening neurological genetic diseases.

AveXis was acquired by Novartis in 2018 for $9B.
Total Funding
Available in Pro
Last Funding
Available in Pro
Acquisitions
0
Monthly Visits
Available in Pro
Contacts
41

Company Details

Funding & Financials

Pro
Total funding
Funding rounds
Last funding
Last funding type
Last funding date
Funding status
Total equity funding
Revenue range

IPO & Stock

IPO status
Delisted
Ticker
AVXS
Exchange
NASDAQ
IPO date
Feb 11, 2016
Raised at IPO
$95M
Valuation at IPO
$430M
Delisted
May 15, 2018

Web Traffic

Pro
Monthly visits
Global traffic rank
6-mo avg visits
Visit duration (s)
Pages / visit
Bounce rate
Rank change (mo)

Technology & IP

Active technologies
18
Mobile apps
2
Active products
12

Company Info

Founded
2013
Employees
11-50
Operating status
Closed
Company type
For Profit
Org types
company
Founders
3
News articles
72
HQ
Dallas, Texas, United States
Region
Dallas/Fort Worth Metroplex, Southern US
Exit date
Feb 11, 2016

Signals & Scores

Heat score
Low
Trend (7d)
0.2
Trend (30d)
1.2
Trend (90d)
0

Key People at AveXis

Senior Vice President, General Counsel, and Chief Compliance Officer
Senior Vice President, Chief Financial Officer
41
professional contacts at AveXis
Contact execs at AveXis

Explore 200,000+ acquisitions — free

Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.

Explore all acquisitions

Recent News related to AveXis

Loading news…

FAQs about AveXis

People who checked this page also checked these

Browse the full Acquirezy directory.
AveXis - Company Profile, Full Acquisitions List, Funding and Investments